14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CGIX ranks #14663 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$2.24 (-1.32%)

Volume: 67k

Closed: Oct 15, 2021

Hollow Logo Score: -2.657

Cancer Genetics Stock Forecast

$2.24 (-1.32%)

Volume: 67k

Closed: Oct 15, 2021

Score Hollow Logo -2.657

Cancer Genetics Stock News NASDAQ:CGIX

Cancer Genetics Inc. shares closed this week 69.7% higher than it did at the end of last week. The stock is currently up 142.6% year-to-date, up 36.6% over the past 12 months, and down 90.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.3%. Trading Activity Shares traded as high as $17.50 and as low as $4.01 this week.Shares closed 6e+1% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 10.0% higher than the 10-day average and 143.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 802.8% The company's stock price performance over the past 12 months beats the peer average by 137.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected] © 2020 Kwhen Inc. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASDAQ: ATRC ) Avanos Medical Inc (NYSE: AVNS ) Beigene Ltd (NASDAQ: BGNE ) Bio-Path Holdings Inc (NASDAQ: BPTH ) (announced receipt of third patent related to manufacture of platform technology) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cancer Genetics Inc (NASDAQ: CGIX ) (reacted to an update to merger terms with StemoniX) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Clearside Biomedical Inc (NASDAQ: CLSD ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) Edap Tms SA (NASDAQ: EDAP ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Gamida Cell Ltd (NASDAQ: GMDA ) ( reacted to a positive late-stags readout) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Ideaya Biosciences Inc (NASDAQ: IDYA ) Illumina, Inc. Read more

94 Biggest Movers From Yesterday

09:04am, Thursday, 11'th Feb 2021 Benzinga
Gainers Anchiano Therapeutics Ltd. (NASDAQ: ANCN ) jumped 187.4% to close at $7.96. Bio-Path Holdings, Inc. (NASDAQ: BPTH ) shares surged 126.4% to close at $11.77 on Wednesday after the company announced it received a third U.S. patent grant related to the manufacture of its platform technology. Viant Technology Inc. (NASDAQ: DSP ) climbed 90.9% to close at $47.72 after the company priced 10 million shares at $25 per share to rake in proceeds worth $250 million in an upsized initial public offering (IPO). United States Antimony Corporation (NYSE: UAMY ) climbed 82.6% to close at $1.78 after the company signed non-binding letter of interest regarding the potential supply of antimony with AMBRI. Sundial Growers Inc. (NASDAQ: SNDL ) surged 78.9% to close at $2.95 after jumping over 28% on Tuesday. Tengasco, Inc. (NYSE: TGC ) gained 77.2% to close at $5.05. Tilray, Inc. (NASDAQ: TLRY ) shares gained 50.9% to close at $63.91. Tilray shares jumped more than 40% on Tuesday after the company announced it has entered into an agreement with Grow Pharma to import and distribute Tilray's medical cannabis products into the United Kingdom. Read more

CGIX Stock: Why Cancer Genetics Shares Are Rocketing Higher Today

01:20pm, Wednesday, 10'th Feb 2021 InvestorPlace
CGIX stock is on the move Wednesday ahead of a shareholder vote on its merger with StemoniX. Here's what you should know now. Read more

42 Stocks Moving in Wednesday's Pre-Market Session

07:00am, Wednesday, 10'th Feb 2021 Benzinga
Gainers Cancer Genetics, Inc. (NASDAQ: CGIX) shares rose 200.7% to $17.35 in pre-market trading after climbing over 20% on Tuesday. Cancer Genetics, last … Read more

EFFECT - CANCER GENETICS, INC (0001349929) (Filer) - Stocks News Feed

05:15am, Tuesday, 09'th Feb 2021 Stocks News Feed
Accepted 2021-02-09 00:15:33 Documents Thank you for supporting Stocks News Feed. As an Amazon affiliate, we earn from qualifying purchases. 1 Effectiveness Date 2021-02-08 Registration Form S-3 Document Format Files Mailing Address 201 ROUTE 17 NORTH 2ND FLOOR RUTHERFORD NJ 07070 Business Address 201 ROUTE 17 NORTH 2ND FLOOR RUTHERFORD NJ 07070 201.528.9200 CANCER GENETICS,… Read More »EFFECT – CANCER GENETICS, INC (0001349929) (Filer) Read more
Cancer Genetics Inc. shares closed today 16.7% lower than it did at the end of yesterday. The stock is currently up 44.4% year-to-date, down 7.0% over the past 12 months, and down 94.9% over the past five years. Today, the Dow Jones Industrial Average fell 2.0%, and the S&P 500 fell 2.0%. Trading Activity Shares traded as high as $4.80 and as low as $3.49 this week.Shares closed 3e+1% below its 52-week high and 9e+1% above its 52-week low.Trading volume this week was 212.0% higher than the 10-day average and 178.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 0.9% lower than its 5-day moving average, 10.6% higher than its 20-day moving average, and 25.5% higher than its 90-day moving average. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date beats the peer average by 484.0% The company's stock price performance over the past 12 months lags the peer average by -479.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected] © 2020 Kwhen Inc. Read more
Cancer Genetics Inc. shares closed this week 32.4% higher than it did at the end of last week. The stock is currently up 52.0% year-to-date, down 7.1% over the past 12 months, and down 94.4% over the past five years. This week, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 1.9%. Trading Activity Shares traded as high as $5.95 and as low as $3.05 this week.Shares closed 3e+1% below its 52-week high and 1e+2% above its 52-week low.Trading volume this week was 7.0% higher than the 10-day average and 78.4% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date beats the peer average by 476.3% The company's stock price performance over the past 12 months lags the peer average by -407.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected] © 2020 Kwhen Inc. Read more
RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery… Read more
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical… Read more
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cancer Genetics, Inc. (NasdaqGS: CGIX) with StemoniX, Inc. in a stock-for-stock transaction. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company. If you believe that this transaction undervalues the Company and/or if you wo Read more
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDAQ: PRNB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Revance Therapeutics Inc (NASDAQ: RVNC ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) (FDA granted a third fast-track designation to its lead drug candidate, repotrectinib) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 24) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Kymera Therapeutics Inc (NASDAQ: KYMR ) (IPOed Friday) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Polypid Ltd (NASDAQ: PYPD ) Poseida Therapeutics, Inc. (NASDAQ: PSTX ) Recro Pharma Inc (NASDAQ: REPH ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Tricida Inc (NASDAQ: TCDA ) (FDA rejected its drug to treat metabolic acidosis and requested additional data) Unity Biotechnology Inc (NASDAQ: UBX ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Qiagen Launches Rapid … Read more
NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Cancer Genetics, Inc. (NASDAQ: CGIX) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection… Read more

Why Cancer Genetics Is Trading Higher Today

07:41pm, Monday, 24'th Aug 2020 Benzinga
Cancer Genetics (NASDAQ: CGIX ) shares are trading higher on Monday after the company announced the entry into a definitive merger agreement with StemoniX. Cancer Genetics is in the early stage of precision medicine, enabling individualized therapies in the field of oncology through diagnostic products and services and molecular … Full story available on Benzinga.com Read more
RUTHERFORD, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical… Read more

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE